3C Wins Both Cannabis Cultivation and Extraction/Product Manufacturing Licenses in Denmark
DENVER, Dec. 21, 2017 /PRNewswire/ — 3C Consulting, LLC, together with its medical cannabis partner Cantiva ApS, have been successfully awarded 1 of 11 national cannabis cultivation and extraction/manufacturing licenses after a rigorous application process in Denmark.
We are very proud to have secured both cannabis cultivation and extraction licenses in an exclusive-license country like Denmark. With our partner, Cantiva ApS, we will move forward with our cannabis plans as well as additional industry strategies in Denmark and greater Europe.
Nic Easley, CEO of 3C
These cultivation and extraction license wins establish a beachhead for 3C to expand further into Europe while bolstering our overall global expansion. This pivotal moment marks a new opportunity to do right by patients and we resolve to help set a new standard for the cannabis industry by leveraging what we have learned operating in 22 states and seven countries.
“…I had NEVER seen such a great team, working so hard to succeed at an application. I am, and will forever be impressed by you, and how fast and professional your approach was on these applications,” said Lars Nielsen, CEO of Cantiva ApS Denmark.
Denmark is an early leader in the European cannabis market as medical cannabis laws across Europe become more standardized, and attitudes toward adult recreational cannabis use continue to soften. Of Denmark’s 5.7 million citizens, 1,141,450 suffer with chronic pain; nearly 300,000 have various types of cancer; and 12,800 have multiple sclerosis. The Danish Medicines Agency has approved legal medical cannabis treatments for the above conditions, as well as spinal cord injuries. Approved in 2016, the country’s medical cannabis pilot program goes into effect on January 1, 2018. The program will allow treatment within Denmark’s current medical system using cannabis products such as pills, capsules, transdermal patches, topicals such as balms, lotions, and creams, as well as suppositories.
Over the course of the four year trial program, Danish companies will establish a new standard for pharmaceutical medical cannabis that will lead to research and further medical education and patient care. The opportunity to be one of the first licensed medical cannabis cultivation and extraction/manufacturing businesses in Denmark opens new doors of possibilities.
Learn more about 3C at http://www.3ccannabis.com
